{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-22",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "East Walpole",
      "state": "MA",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Devices",
      "event_id": "63167",
      "recalling_firm": "Siemens Healthcare Diagnostics, Inc",
      "address_1": "333 Coney St",
      "address_2": "N/A",
      "postal_code": "02032-1516",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Worldwide Distribution-USA (nationwide) and the countries of  Australia, Brazil, Canada, Columbia, Japan, Korea, Mexico, New Zealand, Peru, Saudi Arabia, and Spain.",
      "recall_number": "Z-0162-2013",
      "product_description": "Siemens ADVIA Centaur BR Assay: Catalog Number:  US: REF 02419937 (10214722) (50 Tests);  REF 03896216(10334837)(250 Tests) Not  CE Marked; OUS:  REF03204829(10310271)(50 Tests); REF  01157807(1 0314722) (250 Tests) CE  Marked; REF 09010686 (10340081)(250 Tests).    The ADVIA Centaur BR assay is an in vitro diagnostic test for the quantitative serial determination of cancer antigen CA 27.29 in human serum using the ADVIA Centaur and ADVIA Centaur XP systems. The test is intended for use as an aid in monitoring patients previously treated for Stage II or Stage Ill breast cancer. Serial testing for CA 27.29 in the serum of patients who are clinically free of disease should be used in conjunction with other clinical methods used for the early detection of cancer recurrence. The test is also intended for use as an aid in the management of breast cancer patients with metastatic disease by monitoring the progression or regression of disease in response to treatment.",
      "product_quantity": "15,455 kits",
      "reason_for_recall": "BR Assay for CA 27.29 Calibration Interval Change due quality control (QC) results outside of the expected ranges.",
      "recall_initiation_date": "20120911",
      "center_classification_date": "20121027",
      "termination_date": "20160901",
      "report_date": "20121107",
      "code_info": "BR Assay for CA 27.29 BR Assay Kit Lots  ReadyPack¿ Lot Number Ending in 198:.  89291198,86469198,85752198,88939198,  87757198, 85459198, 88319198, 86295198,  85194198   ReadyPack¿ Lot Number Ending in  202:   93573202, 91045202, 93664202, 90880202,  93157202,91126202,90494202.    BR Assay for CA 15-3 ReadyPack BR Assay Kit Lots Lot Number Ending in 199:   87425199,85862199,86949199,85945199",
      "more_code_info": ""
    }
  ]
}